1. Home
  2. SNGX vs CTM Comparison

SNGX vs CTM Comparison

Compare SNGX & CTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNGX
  • CTM
  • Stock Information
  • Founded
  • SNGX 1987
  • CTM 2019
  • Country
  • SNGX United States
  • CTM United States
  • Employees
  • SNGX N/A
  • CTM N/A
  • Industry
  • SNGX Biotechnology: Pharmaceutical Preparations
  • CTM EDP Services
  • Sector
  • SNGX Health Care
  • CTM Technology
  • Exchange
  • SNGX Nasdaq
  • CTM Nasdaq
  • Market Cap
  • SNGX 9.6M
  • CTM 9.5M
  • IPO Year
  • SNGX 1987
  • CTM N/A
  • Fundamental
  • Price
  • SNGX $3.51
  • CTM $0.17
  • Analyst Decision
  • SNGX
  • CTM
  • Analyst Count
  • SNGX 0
  • CTM 0
  • Target Price
  • SNGX N/A
  • CTM N/A
  • AVG Volume (30 Days)
  • SNGX 56.4K
  • CTM 4.4M
  • Earning Date
  • SNGX 11-08-2024
  • CTM 11-13-2024
  • Dividend Yield
  • SNGX N/A
  • CTM N/A
  • EPS Growth
  • SNGX N/A
  • CTM N/A
  • EPS
  • SNGX N/A
  • CTM N/A
  • Revenue
  • SNGX $364,183.00
  • CTM $45,555,964.00
  • Revenue This Year
  • SNGX N/A
  • CTM $29.25
  • Revenue Next Year
  • SNGX $76.64
  • CTM N/A
  • P/E Ratio
  • SNGX N/A
  • CTM N/A
  • Revenue Growth
  • SNGX N/A
  • CTM 3.12
  • 52 Week Low
  • SNGX $1.83
  • CTM $0.12
  • 52 Week High
  • SNGX $32.00
  • CTM $0.40
  • Technical
  • Relative Strength Index (RSI)
  • SNGX 49.14
  • CTM 50.72
  • Support Level
  • SNGX $3.50
  • CTM $0.15
  • Resistance Level
  • SNGX $3.74
  • CTM $0.19
  • Average True Range (ATR)
  • SNGX 0.20
  • CTM 0.02
  • MACD
  • SNGX 0.01
  • CTM 0.00
  • Stochastic Oscillator
  • SNGX 47.37
  • CTM 53.19

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

About CTM Castellum Inc.

Castellum Inc is engaged in providing information technology services. The company provides financial services, healthcare, and other users of large data applications with services that include intelligence analysis, software development, software engineering, program management, strategic and mission planning, information assurance, cybersecurity and policy support, data analytics, and MBSE. In addition to constantly innovating and enhancing organic capabilities, Castellum is acquiring technology companies in the areas of cybersecurity, information technology, electronic warfare, information warfare, and information operations with businesses in the defense, federal, civilian, and commercial markets.

Share on Social Networks: